



8 October 2021

To the Shareholders of TauRx Pharmaceuticals Ltd. Not Resident in Singapore (each an "Overseas Shareholder")

Dear Sirs

TAURX PHARMACEUTICALS LTD. - RIGHTS ISSUE

1. We refer to the letter to Overseas Shareholders dated 30 August 2021 (the "**30 August 21 Letter**"), pursuant to which TauRx Pharmaceuticals Ltd. (the "**Company**") has informed Overseas Shareholders that the Company is considering to undertake a potential corporate exercise.
2. Further to the 30 August 21 Letter, the Company wishes to inform the Overseas Shareholders that the Company will be undertaking a renounceable rights issue (the "**Rights Issue**") of new ordinary shares in the capital of the Company (the "**Rights Shares**") and warrants (the "**Warrants**"), in accordance with the share issuance mandate obtained from the shareholders of the Company (the "**Shareholders**") at the annual general meeting of the Company dated 11 December 2020. The documents relating to the Rights Issue (the "**Documents**") will be despatched on or around 15 October 2021.
3. Please be informed that only Shareholders on record as at 5.00 p.m. on 11 October 2021 (the "**Books Closure Date**") and (a) whose registered addresses with the Company are in Singapore as at the Books Closure Date, or (b) who have, by the Specified Date (as defined below), provided the Company with addresses in Singapore for the service of the notices and documents (the "**Entitled Shareholders**"), are entitled to participate in the Rights Issue and receive the Documents. Overseas Shareholders with registered addresses outside Singapore who do not provide an address in Singapore for the service of the Documents by the Specified Date will not be entitled to participate in the Rights Issue.
4. **If you wish to receive the Documents and all future notices and documents in relation to the Rights Issue, please complete and return the enclosed Appendix to this Letter, as soon as possible by no later than 28 October 2021 (the "Specified Date").**
5. Overseas Shareholders should take note of the indicative timetable in respect of the Rights Issue, as set out below. The timeline below is indicative only and subject to change.

Books Closure Date	:	11 October 2021 at 5.00 p.m.
Despatch of the Documents	:	15 October 2021
Opening date and time for the Rights Issue	:	15 October 2021 at 9.00 a.m.
Last date and time for splitting	:	3 November 2021 at 5.00 p.m.

Last date and time for acceptance and payment : 11 November 2021 at 5.00 p.m.

Last date and time for acceptance and payment by renounees (i.e. a person, being an existing Entitled Shareholder, to whom an Entitled Shareholder renounces its provisional allotment of the Rights Shares and the Warrants under the Rights Issue) : 11 November 2021 at 5.00 p.m.

Last date and time for excess application and payment : 11 November 2021 at 5.00 p.m.

6. **This Letter is sent to you solely for providing an address in Singapore for the service of all future notices and documents only, and may not be relied upon by you for any other purpose. This Letter may not be used for the purpose of, and does not constitute, an offer, invitation to or solicitation by or on behalf of anyone in any jurisdiction or in any circumstances in which such an offer, invitation or solicitation is unlawful or not authorised or to any person to whom it is unlawful to make such an offer, invitation or solicitation.**
7. **If you are in doubt about this Letter, you should consult your stockbroker, bank manager, solicitor or other professional adviser immediately.**

Yours faithfully



Dr Seng Shay Way
For and on behalf of
TauRx Pharmaceuticals Ltd.

Appendix

To: TauRx Pharmaceuticals Ltd.
c/o Wong Kin Meng & Co
3 Shenton Way
#21-04
Shenton House
Singapore 068805

I/We, _____ (please insert name), of
_____ (please insert address), hereby
notify TauRx Pharmaceuticals Ltd. that with immediate effect all notices and documents in relation to
the Rights Issue to be served on or delivered to me/us in my/our capacity as shareholder of TauRx
Pharmaceuticals Ltd. shall be served on or delivered to the following address in Singapore:

Signature: _____

Date: _____

Telephone number: _____

***In the interest of time, Overseas Shareholders may forward this Appendix by email to
shareregistry@taurx.com***